EXXUA addresses frequent causes of treatment discontinuation with first-line SSRIs and SNRIsNow commercially available through retail pharmacies and participating Aytu…
At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the…
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia and…
ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.USANewsGroup.com News Commentary VANCOUVER, BC, Jan. 16, 2026 /PRNewswire/ -- The medical imaging world…
KELOWNA, BC, Jan. 16, 2026 /PRNewswire/ -- Doseology Sciences Inc. (CSE: MOOD) (PINK: DOSEF) (FSE: VU70) ("Doseology" or the "Company") a…
Expanding adoption, evidence, and innovation to support earlier identification and intervention across care and researchBOSTON, Jan. 16, 2026 /PRNewswire/ --…
CBTN will help scale real-time, interoperable data across more than 200 hospitals nationwide.PHILADELPHIA, Jan. 15, 2026 /PRNewswire/ -- The Children's…
CBTN will help scale real-time, interoperable data across more than 200 hospitals nationwide.PHILADELPHIA, Jan. 15, 2026 /PRNewswire/ -- The Children's…
COPENHAGEN, Denmark, Jan. 15, 2026 /PRNewswire/ -- The Novo Nordisk Foundation has allocated up to DKK 5.5 billion (EUR 736 million)…
Adaptive Learning Platform Delivers Personalized EHR Training at Scale, Achieving Higher Provider Satisfaction and Dramatic Efficiency Gains as reported by…